The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Disease Control and Prevention Vaccine-Global Market Insights and Sales Trends 2025
Synopsis
Vaccines are biological entity used to activate acquired immunity to control or prevent particular disease or a group of disease. Immunization is carried out in infants as well as in adults. Vaccination against various bacterial and viral diseases is an integral part of infectious disease control world-wide.
The global Disease Control and Prevention Vaccine market size is expected to reach US$ 84190 million by 2029, growing at a CAGR of 10.4% from 2023 to 2029. The market is mainly driven by the significant applications of Disease Control and Prevention Vaccine in various end use industries. The expanding demands from the Pediatric Vaccine and Adult Vaccine, are propelling Disease Control and Prevention Vaccine market. Live-Attenuated, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inactivated segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Disease Control and Prevention Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Disease Control and Prevention Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Disease Control and Prevention Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Disease Control and Prevention Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Disease Control and Prevention Vaccine covered in this report include GSK, Merck & Co., Inc, Pfizer, Sanofi, AstraZeneca PLC, Sinovac Biotech Ltd, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd and Daiichi Sankyo, etc.
The global Disease Control and Prevention Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Merck & Co., Inc
Pfizer
Sanofi
AstraZeneca PLC
Sinovac Biotech Ltd
Astellas Pharma Inc
Serum Institute of India Pvt. Ltd
Daiichi Sankyo
Abbott Laboratories
Bharat Biotech International
Bavarian Nordic A/S
CSL Limited
Emergent BioSolutions Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novavax Inc
Panacea Biotec Ltd
Takeda Pharmaceutical Company Limited
Global Disease Control and Prevention Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Disease Control and Prevention Vaccine market, Segment by Type:
Live-Attenuated
Inactivated
Recombinant Sub Unit and Toxoid
Global Disease Control and Prevention Vaccine market, by Application
Pediatric Vaccine
Adult Vaccine
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Disease Control and Prevention Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Vaccines are biological entity used to activate acquired immunity to control or prevent particular disease or a group of disease. Immunization is carried out in infants as well as in adults. Vaccination against various bacterial and viral diseases is an integral part of infectious disease control world-wide.
The global Disease Control and Prevention Vaccine market size is expected to reach US$ 84190 million by 2029, growing at a CAGR of 10.4% from 2023 to 2029. The market is mainly driven by the significant applications of Disease Control and Prevention Vaccine in various end use industries. The expanding demands from the Pediatric Vaccine and Adult Vaccine, are propelling Disease Control and Prevention Vaccine market. Live-Attenuated, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Inactivated segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Disease Control and Prevention Vaccine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Disease Control and Prevention Vaccine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Disease Control and Prevention Vaccine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Disease Control and Prevention Vaccine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Disease Control and Prevention Vaccine covered in this report include GSK, Merck & Co., Inc, Pfizer, Sanofi, AstraZeneca PLC, Sinovac Biotech Ltd, Astellas Pharma Inc, Serum Institute of India Pvt. Ltd and Daiichi Sankyo, etc.
The global Disease Control and Prevention Vaccine market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Merck & Co., Inc
Pfizer
Sanofi
AstraZeneca PLC
Sinovac Biotech Ltd
Astellas Pharma Inc
Serum Institute of India Pvt. Ltd
Daiichi Sankyo
Abbott Laboratories
Bharat Biotech International
Bavarian Nordic A/S
CSL Limited
Emergent BioSolutions Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Mitsubishi Tanabe Pharma Corporation
Novavax Inc
Panacea Biotec Ltd
Takeda Pharmaceutical Company Limited
Global Disease Control and Prevention Vaccine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Disease Control and Prevention Vaccine market, Segment by Type:
Live-Attenuated
Inactivated
Recombinant Sub Unit and Toxoid
Global Disease Control and Prevention Vaccine market, by Application
Pediatric Vaccine
Adult Vaccine
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Disease Control and Prevention Vaccine companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Disease Control and Prevention Vaccine
1.1 Disease Control and Prevention Vaccine Market Overview
1.1.1 Disease Control and Prevention Vaccine Product Scope
1.1.2 Disease Control and Prevention Vaccine Market Status and Outlook
1.2 Global Disease Control and Prevention Vaccine Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Disease Control and Prevention Vaccine Market Size by Region (2018-2029)
1.4 Global Disease Control and Prevention Vaccine Historic Market Size by Region (2018-2023)
1.5 Global Disease Control and Prevention Vaccine Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Disease Control and Prevention Vaccine Market Size (2018-2029)
1.6.1 North America Disease Control and Prevention Vaccine Market Size (2018-2029)
1.6.2 Europe Disease Control and Prevention Vaccine Market Size (2018-2029)
1.6.3 Asia-Pacific Disease Control and Prevention Vaccine Market Size (2018-2029)
1.6.4 Latin America Disease Control and Prevention Vaccine Market Size (2018-2029)
1.6.5 Middle East & Africa Disease Control and Prevention Vaccine Market Size (2018-2029)
2 Disease Control and Prevention Vaccine Market by Type
2.1 Introduction
2.1.1 Live-Attenuated
2.1.2 Inactivated
2.1.3 Recombinant Sub Unit and Toxoid
2.2 Global Disease Control and Prevention Vaccine Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Disease Control and Prevention Vaccine Historic Market Size by Type (2018-2023)
2.2.2 Global Disease Control and Prevention Vaccine Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Disease Control and Prevention Vaccine Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Disease Control and Prevention Vaccine Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Disease Control and Prevention Vaccine Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Disease Control and Prevention Vaccine Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Disease Control and Prevention Vaccine Revenue Breakdown by Type (2018-2029)
3 Disease Control and Prevention Vaccine Market Overview by Application
3.1 Introduction
3.1.1 Pediatric Vaccine
3.1.2 Adult Vaccine
3.2 Global Disease Control and Prevention Vaccine Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Disease Control and Prevention Vaccine Historic Market Size by Application (2018-2023)
3.2.2 Global Disease Control and Prevention Vaccine Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Disease Control and Prevention Vaccine Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Disease Control and Prevention Vaccine Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Disease Control and Prevention Vaccine Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Disease Control and Prevention Vaccine Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Disease Control and Prevention Vaccine Revenue Breakdown by Application (2018-2029)
4 Disease Control and Prevention Vaccine Competition Analysis by Players
4.1 Global Disease Control and Prevention Vaccine Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Disease Control and Prevention Vaccine as of 2022)
4.3 Date of Key Players Enter into Disease Control and Prevention Vaccine Market
4.4 Global Top Players Disease Control and Prevention Vaccine Headquarters and Area Served
4.5 Key Players Disease Control and Prevention Vaccine Product Solution and Service
4.6 Competitive Status
4.6.1 Disease Control and Prevention Vaccine Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GSK
5.1.1 GSK Profile
5.1.2 GSK Main Business
5.1.3 GSK Disease Control and Prevention Vaccine Products, Services and Solutions
5.1.4 GSK Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.1.5 GSK Recent Developments
5.2 Merck & Co., Inc
5.2.1 Merck & Co., Inc Profile
5.2.2 Merck & Co., Inc Main Business
5.2.3 Merck & Co., Inc Disease Control and Prevention Vaccine Products, Services and Solutions
5.2.4 Merck & Co., Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.2.5 Merck & Co., Inc Recent Developments
5.3 Pfizer
5.3.1 Pfizer Profile
5.3.2 Pfizer Main Business
5.3.3 Pfizer Disease Control and Prevention Vaccine Products, Services and Solutions
5.3.4 Pfizer Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Disease Control and Prevention Vaccine Products, Services and Solutions
5.4.4 Sanofi Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.4.5 Sanofi Recent Developments
5.5 AstraZeneca PLC
5.5.1 AstraZeneca PLC Profile
5.5.2 AstraZeneca PLC Main Business
5.5.3 AstraZeneca PLC Disease Control and Prevention Vaccine Products, Services and Solutions
5.5.4 AstraZeneca PLC Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.5.5 AstraZeneca PLC Recent Developments
5.6 Sinovac Biotech Ltd
5.6.1 Sinovac Biotech Ltd Profile
5.6.2 Sinovac Biotech Ltd Main Business
5.6.3 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Products, Services and Solutions
5.6.4 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.6.5 Sinovac Biotech Ltd Recent Developments
5.7 Astellas Pharma Inc
5.7.1 Astellas Pharma Inc Profile
5.7.2 Astellas Pharma Inc Main Business
5.7.3 Astellas Pharma Inc Disease Control and Prevention Vaccine Products, Services and Solutions
5.7.4 Astellas Pharma Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.7.5 Astellas Pharma Inc Recent Developments
5.8 Serum Institute of India Pvt. Ltd
5.8.1 Serum Institute of India Pvt. Ltd Profile
5.8.2 Serum Institute of India Pvt. Ltd Main Business
5.8.3 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Products, Services and Solutions
5.8.4 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.8.5 Serum Institute of India Pvt. Ltd Recent Developments
5.9 Daiichi Sankyo
5.9.1 Daiichi Sankyo Profile
5.9.2 Daiichi Sankyo Main Business
5.9.3 Daiichi Sankyo Disease Control and Prevention Vaccine Products, Services and Solutions
5.9.4 Daiichi Sankyo Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.9.5 Daiichi Sankyo Recent Developments
5.10 Abbott Laboratories
5.10.1 Abbott Laboratories Profile
5.10.2 Abbott Laboratories Main Business
5.10.3 Abbott Laboratories Disease Control and Prevention Vaccine Products, Services and Solutions
5.10.4 Abbott Laboratories Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.10.5 Abbott Laboratories Recent Developments
5.11 Bharat Biotech International
5.11.1 Bharat Biotech International Profile
5.11.2 Bharat Biotech International Main Business
5.11.3 Bharat Biotech International Disease Control and Prevention Vaccine Products, Services and Solutions
5.11.4 Bharat Biotech International Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.11.5 Bharat Biotech International Recent Developments
5.12 Bavarian Nordic A/S
5.12.1 Bavarian Nordic A/S Profile
5.12.2 Bavarian Nordic A/S Main Business
5.12.3 Bavarian Nordic A/S Disease Control and Prevention Vaccine Products, Services and Solutions
5.12.4 Bavarian Nordic A/S Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.12.5 Bavarian Nordic A/S Recent Developments
5.13 CSL Limited
5.13.1 CSL Limited Profile
5.13.2 CSL Limited Main Business
5.13.3 CSL Limited Disease Control and Prevention Vaccine Products, Services and Solutions
5.13.4 CSL Limited Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.13.5 CSL Limited Recent Developments
5.14 Emergent BioSolutions Inc
5.14.1 Emergent BioSolutions Inc Profile
5.14.2 Emergent BioSolutions Inc Main Business
5.14.3 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Products, Services and Solutions
5.14.4 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.14.5 Emergent BioSolutions Inc Recent Developments
5.15 Inovio Pharmaceuticals Inc
5.15.1 Inovio Pharmaceuticals Inc Profile
5.15.2 Inovio Pharmaceuticals Inc Main Business
5.15.3 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Products, Services and Solutions
5.15.4 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.15.5 Inovio Pharmaceuticals Inc Recent Developments
5.16 Johnson & Johnson
5.16.1 Johnson & Johnson Profile
5.16.2 Johnson & Johnson Main Business
5.16.3 Johnson & Johnson Disease Control and Prevention Vaccine Products, Services and Solutions
5.16.4 Johnson & Johnson Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.16.5 Johnson & Johnson Recent Developments
5.17 Mitsubishi Tanabe Pharma Corporation
5.17.1 Mitsubishi Tanabe Pharma Corporation Profile
5.17.2 Mitsubishi Tanabe Pharma Corporation Main Business
5.17.3 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Products, Services and Solutions
5.17.4 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.17.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
5.18 Novavax Inc
5.18.1 Novavax Inc Profile
5.18.2 Novavax Inc Main Business
5.18.3 Novavax Inc Disease Control and Prevention Vaccine Products, Services and Solutions
5.18.4 Novavax Inc Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.18.5 Novavax Inc Recent Developments
5.19 Panacea Biotec Ltd
5.19.1 Panacea Biotec Ltd Profile
5.19.2 Panacea Biotec Ltd Main Business
5.19.3 Panacea Biotec Ltd Disease Control and Prevention Vaccine Products, Services and Solutions
5.19.4 Panacea Biotec Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.19.5 Panacea Biotec Ltd Recent Developments
5.20 Takeda Pharmaceutical Company Limited
5.20.1 Takeda Pharmaceutical Company Limited Profile
5.20.2 Takeda Pharmaceutical Company Limited Main Business
5.20.3 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Products, Services and Solutions
5.20.4 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Revenue (US$ Million) & (2018-2023)
5.20.5 Takeda Pharmaceutical Company Limited Recent Developments
6 North America
6.1 North America Disease Control and Prevention Vaccine Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Disease Control and Prevention Vaccine Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Disease Control and Prevention Vaccine Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Disease Control and Prevention Vaccine Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Disease Control and Prevention Vaccine Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Disease Control and Prevention Vaccine Market Dynamics
11.1 Disease Control and Prevention Vaccine Industry Trends
11.2 Disease Control and Prevention Vaccine Market Drivers
11.3 Disease Control and Prevention Vaccine Market Challenges
11.4 Disease Control and Prevention Vaccine Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
